Last reviewed · How we verify
Methergine — Competitive Intelligence Brief
marketed
5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 1A
Other
Small molecule
Live · refreshed every 30 min
Target snapshot
Methergine (Methergine) — University of South Florida.
Comparator set (1 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Methergine TARGET | Methergine | University of South Florida | marketed | 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 1A | ||
| XANOMELINE | XANOMELINE | marketed | 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 1A | 2024-01-01 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Methergine CI watch — RSS
- Methergine CI watch — Atom
- Methergine CI watch — JSON
- Methergine alone — RSS
Cite this brief
Drug Landscape (2026). Methergine — Competitive Intelligence Brief. https://druglandscape.com/ci/methergine. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing